AI Verdict
KURA has stronger fundamentals based on our AI analysis.
KURA vs KTTAW Fundamental Comparison
| Metric | KURA | KTTAW |
|---|---|---|
| Revenue | $67.5M | $486,559.0 |
| Net Income | $-278.7M | $-20.4M |
| Net Margin | -412.9% | -4,198.4% |
| ROE | -160.0% | -37.0% |
| ROA | -37.7% | -33.9% |
| Current Ratio | 6.06x | 11.35x |
| Debt/Equity | 0.06x | 0.00x |
| EPS | $-3.18 | $-2.91 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KURA vs KTTAW: Frequently Asked Questions
Is KURA or KTTAW a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KURA has stronger fundamentals. KURA is rated HOLD (72% confidence) while KTTAW is rated SELL (72% confidence). This is not investment advice.
How does KURA compare to KTTAW fundamentally?
Kura Oncology, Inc. has ROE of -160.0% vs Pasithea Therapeutics Corp.'s -37.0%. Net margins are -412.9% vs -4,198.4% respectively.
Which stock pays higher dividends, KURA or KTTAW?
KURA has a dividend yield of N/A or no dividend while KTTAW has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KURA or KTTAW for long term?
For long-term investing, consider that KURA has HOLD rating with 72% confidence, while KTTAW has SELL rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KURA vs KTTAW?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KURA vs KTTAW, the AI consensus favors KURA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.